Skip to main content
Erschienen in: Diseases of the Colon & Rectum 8/2005

01.08.2005 | Original Contributions

Intensity of Tumor Budding and Its Prognostic Implications in Invasive Colon Carcinoma

verfasst von: Ki-Jae Park, M.D., Hong-Jo Choi, M.D., Mee-Sook Roh, M.D., Hyuk-Chan Kwon, M.D., Choongrak Kim, Ph.D.

Erschienen in: Diseases of the Colon & Rectum | Ausgabe 8/2005

Einloggen, um Zugang zu erhalten

PURPOSE

The aim of this study was to assess the intensity of tumor budding in colon carcinoma quantitatively and to determine its correlation with malignancy potential.

METHODS

The intensities of tumor budding at the invasive front of surgical specimens from 174 patients with well-differentiated or moderately differentiated colon carcinoma were investigated. Differences in intensity among clinicopathologic parameters were compared, and recurrences and survivals were analyzed in accordance with degree of the intensity.

RESULTS

Tumor budding was identified in 155 patients (89 percent) and the mean intensity (± standard deviation) of budding was, on the whole, 6.6 ± 5.6. Intensity was significantly higher in tumors with lymphatic and vascular invasion than in those without (9.1 ± 6.6 vs. 4.8 ± 3.9 and 9.8 ± 6.1 vs. 5.4 ± 4.9; P < 0.0001, respectively). It became significantly higher with increasing T and N stage (P = 0.0013 and < 0.0001, respectively). Both the Cox model and the linear logistic regression indicated that higher intensity was significantly associated with higher risk of postoperative recurrence (P = 0.017 and 0.0001, respectively). When patients were stratified into four groups based on the quartiles of the distribution of intensity, the group of higher quartiles showed significantly less favorable outcome in terms of both five-year disease-free (P = 0.0039) and overall survival (P = 0.0263). The cutoff of the intensity considered to be the best indicator for separating patients with regard to survival was third quartiles (intensity, 9). Based on multivariate analysis, the intensity of budding proved to be a significant covariate associated with disease-free survival (hazard ratio, 2.061; P = 0.0066).

CONCLUSIONS

The intensity of tumor budding at the invasive margin is suggested to be a significant pathologic index, indicating higher malignancy potential and the intensity greater than nine may be considered an adverse prognostic indicator in patients with colon carcinoma.
Literatur
1.
Zurück zum Zitat Morodomi, T, Isomoto, H, Shirouzu, K, Kakegawa, K, Irie, K, Morimatsu, M 1989An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancerCancer6353943PubMed Morodomi, T, Isomoto, H, Shirouzu, K, Kakegawa, K, Irie, K, Morimatsu, M 1989An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancerCancer6353943PubMed
2.
Zurück zum Zitat Hase, K, Shatney, C, Johnson, D, Trollope, M, Vierra, M 1993Prognostic value of tumor “budding” in patients with colorectal cancerDis Colon Rectum3662735PubMed Hase, K, Shatney, C, Johnson, D, Trollope, M, Vierra, M 1993Prognostic value of tumor “budding” in patients with colorectal cancerDis Colon Rectum3662735PubMed
3.
Zurück zum Zitat Okuyama, T, Oya, M, Ishikawa, H 2003Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinomaJ Surg Oncol83427CrossRefPubMed Okuyama, T, Oya, M, Ishikawa, H 2003Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinomaJ Surg Oncol83427CrossRefPubMed
4.
Zurück zum Zitat Ueno, H, Murphy, J, Jass, JR, Mochizuki, H, Talbot, IC 2002Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancerHistopathology4012732CrossRefPubMed Ueno, H, Murphy, J, Jass, JR, Mochizuki, H, Talbot, IC 2002Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancerHistopathology4012732CrossRefPubMed
5.
Zurück zum Zitat Tanaka, M, Hashiguchi, Y, Ueno, H, Hase, K, Mochizuki, H 2003Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for Stage II, T3 colon cancerDis Colon Rectum4610549CrossRefPubMed Tanaka, M, Hashiguchi, Y, Ueno, H, Hase, K, Mochizuki, H 2003Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for Stage II, T3 colon cancerDis Colon Rectum4610549CrossRefPubMed
6.
Zurück zum Zitat Okuyama, T, Oya, M, Ishikawa, H 2002Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinomaDis Colon Rectum4562834CrossRefPubMed Okuyama, T, Oya, M, Ishikawa, H 2002Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinomaDis Colon Rectum4562834CrossRefPubMed
7.
Zurück zum Zitat Jass JR, Sobin LH. Histologic typing of intestinal tumors. In WHO international histological classification of tumors. 2th ed. Berlin: Springer-Verlag, 1989 Jass JR, Sobin LH. Histologic typing of intestinal tumors. In WHO international histological classification of tumors. 2th ed. Berlin: Springer-Verlag, 1989
8.
Zurück zum Zitat Dukes, CE 1932The classification of cancer of the rectumJ Pathol Bacteriol3532332 Dukes, CE 1932The classification of cancer of the rectumJ Pathol Bacteriol3532332
9.
Zurück zum Zitat Cox, DR 1972Regression models and life tablesJ R Stat Soc Series B34187220 Cox, DR 1972Regression models and life tablesJ R Stat Soc Series B34187220
10.
Zurück zum Zitat McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman and Hall, 1989 McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman and Hall, 1989
11.
Zurück zum Zitat Mantel, N 1966Evaluation of survival data and two new rank order statistics arising in its considerationCancer Chemother Rep5016370PubMed Mantel, N 1966Evaluation of survival data and two new rank order statistics arising in its considerationCancer Chemother Rep5016370PubMed
12.
Zurück zum Zitat Imai, T 1954The growth of human carcinoma: a morphological analysis [in Japanese]Fukuoka Igaku Zasshi4572102 Imai, T 1954The growth of human carcinoma: a morphological analysis [in Japanese]Fukuoka Igaku Zasshi4572102
13.
Zurück zum Zitat Hase, K, Shatney, CH, Mochizuki, H, et al. 1995Long-term results of curative resection of “minimally invasive” colorectal cancerDis Colon Rectum381926PubMed Hase, K, Shatney, CH, Mochizuki, H,  et al. 1995Long-term results of curative resection of “minimally invasive” colorectal cancerDis Colon Rectum381926PubMed
14.
Zurück zum Zitat Teixeira, CR, Tanaka, S, Haruma, K, et al. 1994Carcinoembryonic antigen staining patterns at the invasive tumor margin predict the malignant potential of colorectal carcinomaOncology5122833PubMed Teixeira, CR, Tanaka, S, Haruma, K,  et al. 1994Carcinoembryonic antigen staining patterns at the invasive tumor margin predict the malignant potential of colorectal carcinomaOncology5122833PubMed
15.
Zurück zum Zitat Nowell, PC 1986Mechanisms of tumor progressionCancer Res4622037PubMed Nowell, PC 1986Mechanisms of tumor progressionCancer Res4622037PubMed
16.
Zurück zum Zitat Frost, P, Levin, B 1992Clinical implications of metastatic processLancet339145861PubMed Frost, P, Levin, B 1992Clinical implications of metastatic processLancet339145861PubMed
17.
Zurück zum Zitat Masaki, T, Matsuoka, H, Sugiyama, M, et al. 2003Laminin-5 γ2 chain expression as a possible determinant of tumor aggressiveness in T1 colorectal carcinomasDig Dis Sci482728PubMed Masaki, T, Matsuoka, H, Sugiyama, M,  et al. 2003Laminin-5 γ2 chain expression as a possible determinant of tumor aggressiveness in T1 colorectal carcinomasDig Dis Sci482728PubMed
18.
Zurück zum Zitat Masaki, T, Goto, A, Sugiyama, M, et al. 2001Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinomaCancer92253946PubMed Masaki, T, Goto, A, Sugiyama, M,  et al. 2001Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinomaCancer92253946PubMed
19.
Zurück zum Zitat Masaki, T, Sugiyama, M, Matsuoka, H, et al. 2003Coexpression of matrilysin and laminin-5 gamma2 chain may contribute to tumor cell migration in colorectal carcinomasDig Dis Sci4812627PubMed Masaki, T, Sugiyama, M, Matsuoka, H,  et al. 2003Coexpression of matrilysin and laminin-5 gamma2 chain may contribute to tumor cell migration in colorectal carcinomasDig Dis Sci4812627PubMed
20.
Zurück zum Zitat Sordat, I, Rousselle, P, Chaubert, P, et al. 2000Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environmentInt J Cancer8870817PubMed Sordat, I, Rousselle, P, Chaubert, P,  et al. 2000Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environmentInt J Cancer8870817PubMed
21.
Zurück zum Zitat Simon, R, Altman, DG 1994Statistical aspects of prognostic factor studies in oncologyBr J Cancer6997985PubMed Simon, R, Altman, DG 1994Statistical aspects of prognostic factor studies in oncologyBr J Cancer6997985PubMed
22.
Zurück zum Zitat Okuyama, T, Oya, M, Yamaguchi, M 2002Budding (Sprouting) as a useful prognostic marker in colorectal mucinous carcinomaJpn J Clin Oncol324126PubMed Okuyama, T, Oya, M, Yamaguchi, M 2002Budding (Sprouting) as a useful prognostic marker in colorectal mucinous carcinomaJpn J Clin Oncol324126PubMed
Metadaten
Titel
Intensity of Tumor Budding and Its Prognostic Implications in Invasive Colon Carcinoma
verfasst von
Ki-Jae Park, M.D.
Hong-Jo Choi, M.D.
Mee-Sook Roh, M.D.
Hyuk-Chan Kwon, M.D.
Choongrak Kim, Ph.D.
Publikationsdatum
01.08.2005
Erschienen in
Diseases of the Colon & Rectum / Ausgabe 8/2005
Print ISSN: 0012-3706
Elektronische ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-005-0060-6

Weitere Artikel der Ausgabe 8/2005

Diseases of the Colon & Rectum 8/2005 Zur Ausgabe

OriginalPaper

Announcements

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.